Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346183 | 0.82 | ANPEP (0.41) | ANPEPABHD6HTR2A | |
| SCHEMBL7346194 | 0.82 | ANPEP (0.41) | ANPEPABHD6HTR2A | |
| SCHEMBL7346189 | 0.82 | ANPEP (0.41) | ANPEPABHD6HTR2A | |
| SCHEMBL6204851 | 0.75 | MAPK1 (0.52) | MAPK1NAMPTGPR119NR1H2MEN1 | |
| SCHEMBL2902496 | 0.72 | NAMPT (0.53) | MAPK1DDB1CRBNNAMPTKDM1A | |
| SCHEMBL29813705 | 0.72 | NAMPT (0.53) | MAPK1DDB1CRBNNAMPTKDM1A | |
| SCHEMBL4989954 | 0.71 | ANPEP (0.50) | ANPEPHTR2A | |
| SCHEMBL6204853 | 0.70 | MAPK1 (0.48) | MAPK1NAMPTGPR119NR1H2MEN1 | |
| SCHEMBL30428702 | 0.70 | MEN1 (0.46) | MAPK1DDB1CRBNNAMPTTAOK3 | |
| SCHEMBL8222337 | 0.70 | DRD4 (0.48) | MAPK1DDB1CRBNNAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432944-B1 | ARYLACETAMIDOALANYL DERIVATIVES OF BENZODIAZEPINONES ARE USEFUL FOR INHIBITION OF EXTRACELLULAR DEPOSITION OF BETA-AMYLOID PEPTIDE, THUS TREATS AMYLOIDOSIS, ALZHEIMER'S DISEASE AND DOWN'S SYNDROME | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | APP, BACE1, PSEN1 | MAPK1 875/4885DDB1 978/4885CRBN 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.